Recurrent Endometrial Carcinoma Completed Phase 2 Trials for DB01259 (Lapatinib)

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096447Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerTreatment